Gilead hikes 2026 sales outlook, says Medicare cuts Biktarvy price by 38% starting in 2028

Gilead Sciences hiked its full-year sales outlook on ‌Thursday and reported third-quarter product sales rose 13%, driven by a double-digit percentage jump for its flagship HIV…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.reuters.com)